Funder: Bill and Melinda Gates Foundation
Due Dates: January 31, 2025 (Option A) | May 31, 2025 (Option B)
Funding Amounts: Option A: Up to $750,000 USD for up to 18 months; Option B: Funding and duration flexible, determined per project.
Summary: Supports innovative approaches to reduce monoclonal antibody manufacturing costs to $10/gram to expand access to life-saving therapies globally.
Key Information: Applicants must apply through a legal entity; proposals should focus on manufacturing innovations, not molecule modification or clinical trials.